Question

I am a breastfeeding mother and i want to know if it is safe to use AI3-26374? Is AI3-26374 safe for nursing mother and child? Does AI3-26374 extracts into breast milk? Does AI3-26374 has any long term or short term side effects on infants? Can AI3-26374 influence milk supply or can AI3-26374 decrease milk supply in lactating mothers?

AI3-26374 lactation summary

AI3-26374 is dangerous in breastfeeding
  • DrLact safety Score for AI3-26374 is 7 out of 8 which is considered Dangerous as per our analyses.
  • A safety Score of 7 indicates that usage of AI3-26374 may cause toxic or severe side effects in breastfed baby.
  • Our study of different scientific research indicates that AI3-26374 may cause moderate to high side effects or may affect milk supply in lactating mother.
  • Our suggestion is to use safer alternate options rather than using AI3-26374 .
  • Usage of AI3-26374 is in contradiction to breastfeeding hence if it is must to use AI3-26374 and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About AI3-26374 usage in lactation

Drug is cleared from the body in 7 elimination half-lives. Resuming breastfeeding is likely safe after 10 days of pumping-and-dumping.

Answer by DrLact: About AI3-26374 usage in lactation

No information is available on the use of AI3-26374 during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during AI3-26374 therapy and for 14 days after the last dose.

Alternate Drugs

Dactinomycin(Dangerous)
Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Vinblastine(Dangerous)
Etoposide(Dangerous)
Alemtuzumab(Low Risk)
Dactinomycin(Dangerous)
Pazopanib(Unsafe)
Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Rituximab(Low Risk)
Vinorelbine(Dangerous)
Cyclophosphamide(Dangerous)
Bevacizumab(Low Risk)
Dacarbazine(Dangerous)
Cisplatin(Unsafe)
Busulfan(Dangerous)
Trastuzumab(Unsafe)
Thioguanine(Dangerous)
Cladribine(Dangerous)
Gemcitabine(Dangerous)
Imatinib(Unsafe)
Erlotinib(Unsafe)
Dasatinib(Unsafe)
Docetaxel(Dangerous)
Nilotinib(Unsafe)
Vincristine(Dangerous)
Ipilimumab(Unsafe)
Tamoxifen(Dangerous)
Cetuximab(Unsafe)
Mitoxantrone(Dangerous)
Carboplatin(Dangerous)
Paclitaxel(Dangerous)
Letrozole(Dangerous)
Nivolumab(Unsafe)
Exemestane(Dangerous)
Hydroxyurea(Low Risk)
Fluorouracil(Dangerous)
Dactinomycin(Dangerous)
Dactinomycin(Dangerous)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.